

# PROGRAM BOOK



Indiana Urologic Association  
2017 Annual Meeting  
Saturday, February 18, 2017  
Sheraton Indianapolis City Centre Hotel  
Indianapolis, Indiana

# 2017

Indiana Urologic Association

***President Thomas A. Gardner, MD welcomes you to the IUA 2017 Annual Meeting.***

## IUA Board of Directors 2016 – 2017

### **President**

Thomas A. Gardner, MD

### **President-Elect**

Kenneth G. Ney, MD

### **Secretary/Treasurer**

Ronald S. Suh, MD

### **Immediate Past-President**

Teresa D. Beam, MD, FACS

### **Members-at-Large**

Ronald S. Boris, MD  
Sandra A. McCabe, MD  
Bradley G. Orris, MD

### **North Central Section Representative**

Mark D. Dabagia, MD, FACS

### **President of the IUA NP/PA Association**

Tracy Mullins, FNP, BC

### **2017 Program Planning Committee**

Thomas A. Gardner, MD

### **Associate Director**

Samantha N. Panicola

### **IUA Executive Office**

Two Woodfield Lake  
1100 E. Woodfield Road, Suite 350  
Schaumburg, IL 60173  
Phone: (847) 517-7225  
Fax: (847) 517-7229  
[info@iuaweb.org](mailto:info@iuaweb.org)  
[www.iuaweb.org](http://www.iuaweb.org)

## **Past Presidents**

2013 – 2015	Teresa D. Beam, MD, FACS
2011 – 2013	Mark D. Dabagia, MD
2009 – 2011	Chandru P. Sundaram, MD
2007 – 2009	Samuel T. Thompson, MD
2005 – 2007	Christopher P. Steidle, MD



**Indiana Urologic Association  
2017 Annual Meeting  
Saturday, February 18, 2017  
Indianapolis, Indiana**

2016 - 2017 Board of Directors .....Page 1  
 General Meeting Information .....Page 2  
 Educational Needs & Objectives .....Page 3  
 Accreditation Statement .....Page 4  
 Scientific Program .....Page 5  
 Speaker Biographies .....Page 6

**Exhibit Guide**

Industry Satellite Symposium Event .....Page 10  
 2017 Exhibitors & Contributor.....Page 11  
 Exhibit Floor Plan .....Page 12  
 2017 Promotional Partners..... Back Cover

**Registration/Information Desk Hours**

*Location: Meridian West Lobby*

Saturday, February 18, 2017                      6:45 a.m. – 3:25 p.m.

**Course Description**

The IUA provides a quality support system for the urology physicians in Indiana, and those practicing this specialty in surrounding environs adjacent to the state of Indiana, in the efforts to better serve patients, people and the community areas. The 2017 scientific program will offer presentations on topics of interest to urologists including AUA guideline updates, Indiana health policy updates, health policy reforms and their implications on urologic diseases, social media within urology, the impact of FDA approval of HIFU for prostate cancer, examining evidence from literature for and against vaginal mesh use, and more.

**Educational Needs**

Urologic oncology remains a large aspect of urology which evolves continuously. Being up-to-date on the care of the urologic oncology patient is critical for the practicing urologist or practitioner to understand and incorporate these into their practices.

Diagnosis and treatment of prostate cancer has become very complex with the availability of multiple genomic based tests. Understanding how and when to utilize these tests to allow for the most efficient and effective diagnosis and management of the prostate cancer patient is critical for the practicing urologist or practitioner.

The role of Advanced Practice Providers (APP) continues to increase in the daily practice of urology. It is important for the practicing urologist and urologist in training to understand how best to incorporate APP's into their practice of urology.

Healthcare policy continues to affect all aspects of medicine including urology. With recent political changes, it continues to be vitally important for the practicing urologist to understand how these changes might impact their practices.

Challenging cases in urology are every day experiences. The group analysis of these difficult cases allows the practicing urologist or practitioner to hone their skills in diagnosis and treatment options. Discussing these cases in a forum of experts and peers in the field of urology maximize the benefit of the presentation and discussions. For example, the nuances of diagnosis and treatment of prostate cancer patients needs to be understood by the practicing urologist and advanced practitioner.

The understanding of the genetics of kidney cancer continues to improve. The care of kidney cancer patients by the practicing urologist or advanced practitioner continue to evolve with this information. It continues to be the role of the treating urologist to counsel and inform patients and their potentially affected family member appropriately. Additionally, novel methods of diagnosis and treatment of kidney cancer patients continue to be developed and need to be incorporated by the practicing urologist and advanced practitioner.

**Educational Objectives**

At the conclusion of the IUA 2017 Annual Meeting, attendees should be able to:

1. Explain the current changes in care of the urologic oncology patient.
2. Describe the health policy issues facing urologists in Indiana, the North Central Section region and nationwide.
3. Describe the expanding role of genomic testing in the diagnosis and treatment of prostate cancer patients.
4. Describe and understand the role of the urologist in the genetic counseling associated with the care of kidney cancer patients.
5. Describe and understand the role of novel diagnostic and treatment approaches for kidney cancer patients.

### CONTINUING MEDICAL EDUCATION CREDIT INFORMATION

#### Accreditation

This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the American College of Surgeons and the Indiana Urologic Association. The American College of Surgeons is accredited by the ACCME to provide continuing medical education for physicians.

#### AMA PRA Category 1 Credits™

The American College of Surgeons designates this live activity for a maximum of **5.25** AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.



AMERICAN COLLEGE OF SURGEONS

Inspiring Quality:  
Highest Standards, Better Outcomes

100+years



AMERICAN COLLEGE OF SURGEONS  
DIVISION OF EDUCATION

Accredited with Commendation by the  
Accreditation Council for Continuing Medical Education

Nurses and other healthcare professionals will receive a Certificate of Attendance. For information on the applicability and acceptance of Certificates of Attendance for educational activities certified for *AMA PRA Category 1 Credit™* from organizations accredited by the ACCME, please consult your professional licensing board.

#### General Disclaimer

The statements and opinions contained in this program are solely those of the individual authors and contributors and not of the Indiana Urologic Association. The appearance of the advertisements is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality, or safety. The content of this publication may contain discussion of off-label uses of some of the agents mentioned. Please consult the prescribing information for full disclosure of approved uses. The Indiana Urologic Association disclaims responsibility for any injury to persons or property resulting from any ideas or products referred to in the abstracts or advertisements.

#### Special Assistance

We encourage participation by all individuals. If you have a disability, advance notification of any special needs will help us better serve you. Call (847) 517-7225 if you require special assistance to fully participate in the meeting.

#### Disclosure Information

In compliance with the ACCME Accreditation Criteria, the American College of Surgeons, as the accredited provider of this activity, must ensure that anyone in a position to control the content of the educational activity has disclosed all relevant financial relationships with any commercial interest. All reported conflicts are managed by a designated official to ensure a bias-free presentation.

#### Disclosure Report

The Disclosure Report for this meeting can be found in the course materials provided to you at registration.

## IUA 2017 Annual Meeting

February 18, 2017

Sessions will take place in **Meridian Ballroom West**, unless otherwise noted.  
Speaker and times are subject to change.

### SATURDAY, FEBRUARY 18, 2017

#### OVERVIEW

- 6:45 a.m. - 3:25 p.m. **Registration/Information Desk Open**  
*Location: Meridian West Lobby*
- 7:00 a.m. - 2:30 p.m. **Exhibit Hall Open**  
*Location: Meridian Center*
- 7:00 a.m. - 8:00 a.m. **Breakfast in Exhibit Hall**  
*Location: Meridian Center*

#### GENERAL SESSION

- 7:45 a.m. - 8:00 a.m. **Annual Business Meeting**
- 8:00 a.m. - 8:05 a.m. **Welcome**  
President: Thomas A. Gardner, MD  
Indiana University Medical Center
- 8:05 a.m. - 9:05 a.m. **Contemporary Management of Penile Cancer: The Evolution**  
Guest Speaker: Curtis A. Pettaway, MD  
MD Anderson Cancer Center
- 9:05 a.m. - 9:50 a.m. **Understanding Prostate Cancer Genomics**  
Speaker: Clint Cary, MD, MPH  
Indiana University Medical Center
- 9:50 a.m. - 10:05 a.m. **APP's in Urology**  
Speaker: Christy Krieg, MSN, FNP  
Indiana University Health  
Methodist/University Hospital
- 10:05 a.m. - 10:35 p.m. **Break & Networking in Exhibit Hall**  
*Location: Meridian Center*
- 10:35 a.m. - 10:55 a.m. **Indiana Health Policy Update**  
Speaker: Ronald S. Suh, MD  
Urology of Indiana
- 10:55 a.m. - 11:30 a.m. **Understanding Genetics of Kidney Cancer**  
Speaker: Ronald S. Boris, MD  
IU Health Physicians Urology
- 11:30 a.m. - 12:30 p.m. **Industry Satellite Symposium Lunch**  
*Location: Meridian East*
- 12:30 p.m. - 1:20 p.m. **Resident Case Presentations**  
Judges: Clinton D. Bahler, MD, MS  
Indiana University  
Clint Cary, MD, MPH  
Indiana University Medical Center  
Kenneth G. Ney, MD  
Urology of Indiana
- Back in Black**  
Presenter: Mimi W. Zhang, MD  
Indiana University

**A Narrative of Negotiated Space**  
Presenter: Brian M. Orr, MD  
Indiana University

**On Lock Down**  
Presenter: Michael D. Weintraub, MD  
Indiana University

**Frankenball**  
Presenter: Maria F. Monn, MD  
Indiana University

**Extra Baggage**  
Presenter: Antoin Douglawi, MD  
Indiana University

1:20 p.m. - 1:50 p.m. **Break & Networking in Exhibit Hall**  
*Location: Meridian Center*

1:50 p.m. - 2:30 p.m. **Kidney Cancer and Molecular Imaging Innovations**  
Speaker: Clinton D. Bahler, MD, MS  
Indiana University

2:30 p.m. - 3:15 p.m. **Point-Counterpoint: Prostate Cancer Cases**  
Moderator: Kenneth G. Ney, MD  
Urology of Indiana  
Panelists: Clint Cary, MD, MPH  
Indiana University Medical Center  
Michael O. Koch, MD  
Indiana University Medical Center  
Curtis A. Pettaway, MD  
MD Anderson Cancer Center

3:15 p.m. - 3:25 p.m. **Question & Answer Session/ Wind-up**

#### Disclaimer Statement

Statements, opinions and results of studies contained in the program are those of the presenters/authors and do not reflect the policy or position of the IUA nor does the IUA provide any warranty as to their accuracy or reliability.

Every effort has been made to faithfully reproduce the abstracts as submitted. However, no responsibility is assumed by the IUA for any injury and/or damage to persons or property from any cause including negligence or otherwise, or from any use or operation of any methods, products, instruments, or ideas contained in the material herein.

#### Filming/Photography Statement

No attendee/visitor at the IUA 2017 annual meeting may record, film, tape, photograph, interview, or use any other such media during any presentation, display, or exhibit without the express, advance approval of the IUA Executive Director. This policy applies to all IUA members, non-members, guests, and exhibitors, as well as members of the print, online, or broadcast media.



**Clinton D. Bahler, MD, MS**

Dr. Bahler completed medical school at Indiana University after finishing a degree in biomedical engineering at Purdue University with highest distinction. He completed his urologic surgery residency at Indiana University, and chose to undergo additional specialty fellowship training in laparoscopic and robotic surgery with Dr. Chandru Sundaram at Indiana University. His areas of interest are urologic cancers including kidney, prostate, and adrenal and benign urologic diseases including urinary obstruction and stone disease.



**Ronald S. Boris, MD**

Dr. Boris is a board-certified urologic oncologist and an assistant professor of surgery at the Indiana University in the department of urology. He completed a two-year urologic oncology fellowship at the National Cancer Institute at the National Institutes of Health in Bethesda, MD focusing on surgery for patients with hereditary cancer syndromes. Dr. Boris' primary research interest is in kidney cancer, focusing on the impact that renal tumor histology has on treatment strategies. Dr. Boris also has published extensively on tumor enucleation, a tumor removal technique that may safely minimize renal ischemia and parenchymal loss during partial nephrectomy. He is the creator and program director of the new Hereditary, Multifocal, and Early Onset Kidney Cancer Program at the Simon Cancer Center on the University campus with the goal of creating a world-class multi-disciplinary clinical group to care for, manage, and treat patients at risk for hereditary and early onset renal malignancies.



**Clint Cary, MD, MPH**

Dr. Cary completed his urology residency at Indiana University and then went on to complete a two-year urologic oncology fellowship at the University of California, San Francisco with Peter R. Carroll, MD, MPH. In addition to his fellowship, he completed a Master of Public Health Degree from U.C. Berkeley with a concentration in epidemiology. His clinical interest is in urologic oncology. His research efforts will focus on health services and outcomes research in testis, bladder, and prostate cancer.



**Thomas A. Gardner, MD**

Dr. Gardner has devoted his entire career to the clinical, research and educational advancement of the profession of urology. After completing his residency at New York Hospital and AFUD Fellowship at the University of Virginia, Dr. Gardner worked as a physician-scientist at Indiana University Medical Center. He continued on to Indiana University to develop a research program and build a practice in urologic oncology, where he successfully secured funding to establish a basic and translation research program from 1999 to 2009. He then transitioned his research efforts to clinical trials and has directed a successful clinical trial program. Dr. Gardner moved on to director of clinical trials within the program.

Dr. Gardner specializes in the care of patients with cancers of the urinary tract including prostate, kidney and bladder. He joined the Indiana University faculty after completing an American Foundation of Urologic Diseases Fellowship in Gene Therapy for Prostate and Kidney Cancer at the University of Virginia. He continues to develop novel therapies for patients with urologic cancers and conducts clinical trials through the IU Cancer Center.

He is a participant with AUA and NCS, in addition to continued involvement with abstracts, presentations and a multitude of activities with meetings.



**Michael O. Koch, MD**

Dr. Koch is the Chairman and Professor of Urology at Indiana University School of Medicine having served in that role since 1998. His clinical practice is in urologic oncology. He sees over 200 patients a year and performs approximately 300 surgical cases per year. Dr. Koch has held multiple leadership positions nationally including as trustee and president of the American Board of Urology, chair of the residency review committee for urology for the ACGME, chair of the examination committee for the joint task force of the ABU/AUA, and president of SUCPD and SUU. Locally at IU he serves or has served as chair of the chairs group and multiple other roles. His current academic interests are in prostate and bladder cancer. He started with a department of seven faculty in 1998 which has now grown to 23 clinical faculty, five NP's, and one PhD spanning across seven hospitals.



**Christy Krieg, MSN, FNP**

Ms. Krieg is a native of Indianapolis who returned home after five years in Tucson, Arizona, and was fortunate to be hired out of the Methodist OR to become a nurse for Methodist Urology (now part of IUHP) in 1999. From her early mentors, Jim Lingeman and Ron Steele, she learned the value of patient-centered urologic care, with a focus on stone disease management. After learning more broadly in the field and committing seventeen years to the specialty, she's pretty certain she's a "urology lifer."

In 2007, Christy completed the Master's in Nursing, Family Nurse Practitioner program at IUPUI, and also became a Certified Urologic Nurse Practitioner. She has an independent general Urology practice at IUHP's Methodist location, and sees patients with primarily oncologic and reconstructive needs at the IUHP University clinic. She enjoys teaching through formal lectures at regional and national conferences, and routinely precepts NP students, and medical residents from Urology and Family Practice programs.



**Kenneth G. Ney, MD**

Dr. Ney is originally from Fort Wayne, Indiana. He received his BS from Purdue University in West Lafayette, Indiana, and his medical degree from the Indiana University School of Medicine in Indianapolis. He served his internship and residency in urology at the McGaw Medical Center, Northwestern University School of Medicine, in Chicago, Illinois. He has been in private practice since 1992, and has been working at Urology of Indiana since 2015. His special areas of interest include laparoscopic techniques in urologic surgery, including robotic radical prostatectomy and advanced prostate cancer therapies. Dr. Ney is board certified by the American Board of Urology.



**Curtis A. Pettaway, MD**

Dr. Pettaway is a professor of urology at The University of Texas MD Anderson Cancer Center in Houston Texas. His clinical practice is based on treating patients with genitourinary malignancies including penile, urethral, bladder, and prostate malignancies. Dr. Pettaway has a wealth of experience in the management of penile cancer with one the largest clinical practices in the United States emphasizing novel strategies to reduce the morbidity of therapy while enhancing multimodal therapy for advanced penile cancer. Dr. Pettaway is a member the American Joint Committee Task Force on Staging for Penile Cancer and is the United States Co-Chair for the soon to be initiated InPACT Penile Cancer Clinical Trial. The goal of his prostate related studies is to 1) further define host and molecular markers of cancer progression, and 2) to reduce disparities in prostate cancer outcome among African Americans and the underserved by studying both clinical and biologic correlates of aggressive disease. He is the medical director of the Prostate Outreach Project that has educated and screened over 5,000 men. He directs a National Cancer Institute funded study evaluating the influence of West African ancestry on the incidence and aggressiveness of prostate cancer among African American and Puerto Rican populations.



**Ronald S. Suh, MD**

Dr. Suh serves as Medical Director for Urology of Indiana in Indianapolis, Indiana. In that role, he has navigated strategy and implementation in the ever evolving regulatory and reimbursement environment, from PQRS and EHR Meaningful Use to MIPS, ICD-10 conversion, value-based reimbursement, and alternative payment models. Dr. Suh is a firm believer in the importance of maintaining the autonomous independent practice of medicine, and the necessity and power of measurement to achieve that goal. He has championed the group's participation in the Urological Surgery Quality Collaborative, early adoption of the AUA's Quality Registry (AQUA), including piloting AQUA's Patient Reported Outcomes module, and the LUGPA Medical Director Workgroup. He serves on the CIGNA Physician Advisory Council, the LUGPA Medical Director Benchmarking Committee, and the AUA Data Committee.

He is a general urologist with a specialty focus on urologic prosthetics, reconstructive surgery, and Peyronie's disease. In addition, he serves as Director of Clinical Research for Urology of Indiana, and has been Principal Investigator in trials for prostate cancer, overactive bladder, erectile dysfunction, and Peyronie's disease. Dr. Suh earned his medical degree from the Indiana University School of Medicine and completed his residency training in urology at the University of Michigan Medical Center in Ann Arbor prior to joining Urology of Indiana in 2005. He has a wife and two children and enjoys spending time with them, playing golf, sampling craft beers, and running.



# EXHIBIT GUIDE



Indiana Urologic Association  
2017 Annual Meeting  
Saturday, February 18, 2017  
Sheraton Indianapolis City Centre Hotel  
Indianapolis, Indiana

# 2017

Indiana Urologic Association

# Revolutionary Automated Inventory Management System

**LuproLink uses radio frequency identification (RFID) technology to track each kit from AbbVie—to the clinic—to the patient.**



**Designed to enhance patient care by helping to:**

- Reduce potential administration errors through process automation
- Enable patients to get the right dose at the right time
- Ensure sufficient inventory is on hand using automatic reordering

“I can point to several instances where LuproLink revealed injections that were missed in the paper report. After one year of using LuproLink, the ten office clinical practice has improved patient care, increased its efficiency and eliminated paper record keeping.”

**Michael Burnett, COO**  
Kansas City Urology Care

**LuproLink**

**Right Patient. Right Dose. Right Time.**

**Please stop by the AbbVie booth for a live demonstration of LuproLink.**

**abbvie**

**Exhibit Hall Hours***Location: Meridian Center*

Saturday, February 18, 2017

7:00 a.m. – 2:30 p.m.

**Saturday, February 18, 2017****11:30 a.m. – 12:30 p.m.****Industry Satellite Symposium Lunch****Sponsored By: Astellas/Medivation, A Pfizer Company***Location: Meridian East***"Continuing Care for Your Patients with Metastatic Castration-Resistant Prostate Cancer (CRPC)"****Kenneth Kernan, MD**

Michigan Institute of Urology

Troy, MI



**Thank You to Our 2017 Contributor***(Alphabetical as of 2/6/2017)*

Astellas/Medivation, A Pfizer Company

**Thank You to Our 2017 Exhibitors***(Alphabetical as of 2/6/2017)*

AbbVie

Allergan

Astellas/Medivation, A Pfizer Company

Astellas Pharma US, Inc.

Bayer HealthCare

BK Ultrasound

Boston Scientific Corporation

Coloplast

Cook Medical

Dendreon

Endo Pharmaceuticals

GenomeDx Biosciences Inc.

Genomic Health

iSALUS Healthcare

Janssen Biotech

KARL STORZ

MDxHealth

Myriad Genetic Laboratories

NeoTract, Inc.

NeuWave Medical, Inc.


Olympus America, Inc.

Pacific Edge Diagnostics USA Ltd

Retrophin

TOLMAR Pharmaceuticals

University Compounding



Company Name	Booth #	Company Name	Booth #
AbbVie	2	Genomic Health	16
Allergan	3	iSALUS Healthcare	12
Astellas Pharma	20	Janssen Biotech	7
Astellas/Medivation, a Pfizer Company	1	Karl Storz	8
Bayer HealthCare	19	MDxHealth	5
BK Ultrasound	10	Myriad Genetic Laboratories	22
Boston Scientific	21	NeoTract	23
Coloplast	15	NeuWave Medical	24
Cook Medical	4	Olympus America	6
Dendreon	9	Pacific Edge Diagnostics	14
Endo Pharmaceuticals	17	Retrophin	18
GenomeDx Biosciences	11	TOLMAR Pharmaceuticals	13



# You're Invited



Xtandi<sup>®</sup>  
(enzalutamide)  
40 mg capsules

to a promotional program to learn more about XTANDI.

**When:** Saturday, February 18, 2017 at 11:30 AM

**Where:** Sheraton Indianapolis City Centre | Meridian East  
Indianapolis, IN

**Featuring:** Kenneth Kernen, MD  
Michigan Institute of Urology—Troy, MI

---

**THIS PROMOTIONAL PROGRAM IS SPONSORED BY ASTELLAS PHARMA US, INC. AND/OR MEDIVATION, INC.**

Astellas Pharma US, Inc. ("Astellas") and/or Medivation, Inc., ("Medivation") is subject to U.S. Federal and State transparency laws that require Astellas and/or Medivation to track and report meals and other transfers of value provided to certain U.S. health care professionals (including physicians). To comply with these obligations, for attendees who receive any portion of the meal provided at this program, Astellas and/or Medivation will report the attendee's name and the value of the meal received. Astellas and/or Medivation offer you the option to attend the event but not receive the meal. Please ask the Program Organizer for more information about this opt-out option.

Additional restrictions apply to the following individuals:

**For U.S. Healthcare Providers in Vermont or those affiliated with the U.S. Department of Veterans Affairs or Department of Defense:** Several states and federal agencies in the United States restrict your interactions with Astellas and/or Medivation, including the provision of in-kind benefits (such as meals) at company-sponsored events. If you are a healthcare professional in Vermont or are affiliated with the U.S. Department of Veterans Affairs, Department of Defense, or other federal executive branch entity, Astellas and/or Medivation policies prohibit providing you a meal at this program. If you would like to attend, but not partake in the meal, please refer to the opt-out option below.

**For U.S. Licensed Prescribers in Minnesota:** Under Minnesota law, Astellas and/or Medivation may provide meals and other transfers of value to Minnesota licensed prescribers if the annual (calendar year) aggregate total of all value transfers of any kind from Astellas and/or Medivation to a Minnesota prescriber does not exceed \$50.00 USD, subject to some exceptions. Astellas and/or Medivation has policies and procedures that are intended to help ensure compliance with this annual aggregate limit. If you have questions about your annual aggregate value transfers from Astellas and/or Medivation or the impact of accepting the meal provided at this event on your annual total, please consult the Program Organizer. In addition, if you would like to attend, but not partake in the meal, please refer to the opt-out option below.

**For Foreign Healthcare Providers:** Some foreign countries restrict the provision of or require the reporting of in-kind benefits (such as meals) to health care professionals at company-sponsored events. Astellas and/or Medivation have policies and procedures that are intended to help ensure compliance with these requirements and restrictions. To help ensure compliance with applicable requirements, Astellas and/or Medivation policy prohibits providing a meal to you in conjunction with this event. If you would like to attend, but not partake in the meal, please refer to the opt-out option below.

**Opt-Out Option:** Astellas and/or Medivation offer an opt-out option that allows you to still attend this event but not receive the meal. Please ask the Program Organizer for more information about the opt-out option.

Astellas and/or Medivation have adopted the PhRMA Code on Interactions with Healthcare Professionals, which is designed to foster ethical relationships with healthcare professionals. In accordance with the PhRMA Code, we will not pay for the expenses of a healthcare professional's spouse or guest, and such individuals should not attend the program, unless they have a bona fide professional interest in the information being shared at the program. We appreciate your understanding and support of our commitment to these ethical standards.



# Thank You

to Our 2017 Promotional Partners

## PLATINUM LEVEL PARTNERS

abbvie



## GOLD LEVEL PARTNERS



AUA 2017 Annual Meeting  
May 12 – 16, 2017  
Boston Convention & Exhibition Center  
Boston, Massachusetts

North Central Section of the AUA  
91st Annual Meeting  
November 13 – 17, 2017  
The Westin Kierland Resort and Spa  
Scottsdale, Arizona